Early whole-brain CT perfusion for detection of patients at risk for delayed cerebral ischemia after subarachnoid hemorrhage

Vesna Malinova, MD,1 Karoline Dolatowski, MD,2 Peter Schramm, MD,2,4 Onnen Moerer, MD,3 Veit Rohde, MD,1 and Dorothee Mielke, MD1

Departments of 1Neurosurgery, 2Neuroradiology, and 3Anaesthesiology, Georg-August-University, Göttingen; and 4Department of Neuroradiology, University of Lübeck, Germany

OBJECTIVE This prospective study investigated the role of whole-brain CT perfusion (CTP) studies in the identification of patients at risk for delayed ischemic neurological deficits (DIND) and of tissue at risk for delayed cerebral infarction (DCI).

METHODS Forty-three patients with aneurysmal subarachnoid hemorrhage (aSAH) were included in this study. A CTP study was routinely performed in the early phase (Day 3). The CTP study was repeated in cases of transcranial Doppler sonography (TCD)–measured blood flow velocity (BFV) increase of >50 cm/sec within 24 hours and/or on Day 7 in patients who were intubated/sedated.

RESULTS Early CTP studies revealed perfusion deficits in 14 patients, of whom 10 patients (72%) developed DIND, and 6 of these 10 patients (60%) had DCI. Three of the 14 patients (21%) with early perfusion deficits developed DCI without having had DIND, and the remaining patient (7%) had neither DIND nor DCI. There was a statistically significant correlation between early perfusion deficits and occurrence of DIND and DCI (p < 0.0001). A repeated CTP was performed in 8 patients with a TCD–measured BFV increase >50 cm/sec within 24 hours, revealing a perfusion deficit in 3 of them (38%). Two of the 3 patients (67%) developed DCI without preceding DIND and 1 patient (33%) had DIND without DCI. In 4 of the 7 patients (57%) who were sedated and/or comatose, additional CTP studies on Day 7 showed perfusion deficits. All 4 patients developed DCI.

CONCLUSIONS Whole-brain CTP on Day 3 after aSAH allows early and reliable identification of patients at risk for DIND and tissue at risk for DCI. Additional CTP investigations, guided by TCD–measured BFV increase or persisting coma, do not contribute to information gain.

http://thejns.org/doi/abs/10.3171/2015.6.JNS15720

KEY WORDS subarachnoid hemorrhage; delayed ischemic neurological deficit; CT perfusion; imaging; vasospasm; transcranial Doppler sonography; vascular disorders
tissue at risk is critical, but also challenging due to a multi-
tude of factors. This can result in neurological decline be-
because an examination is of limited value in patients with
a poor Hunt and Hess grade, as well as in patients who are
sedated and/or comatose.

Various diagnostic tools have been applied to detect
patients with cerebral vasospasm after aSAH.3,12,17,18,21,28,29
The ideal diagnostic tool should be noninvasive, easy, fast,
and repeatable, and should allow not only the identification
of patients with vasospasm but also of patients at risk for
DIND and DCI. Digital subtraction angiography (DSA) is
considered the gold standard for the diagnosis of cerebral
vasospasm, but its invasiveness precludes its use for moni-
toring purposes. Transcranial Doppler sonography (TCD)
is a widely used, noninvasive bedside method that is suit-
for daily monitoring.5,8,11,18,22,27,30,32 However, TCD is
dependent on the experience of the investigator and does
not allow the detection of peripheral vessel vasospasm.
Without clinical information, DSA and TCD do not allow
identification of the progression of asymptomatic to sym-
tomatic vasospasm and identification of tissue at risk.11,30

Computed tomography perfusion (CTP) allows visual-
ization of brain perfusion and has been applied in brain tu-
mors, ischemic stroke, and aSAH.1,4,10,12,14,15,17–19,23,25,28,33,36–38
A disadvantage of CTP is the exposure to radiation, which
precludes its frequent use. This is reflected by available
studies, in which CTP was performed once between Days
5 and 14, which represent the days with the highest prob-
ability of vasospasm occurrence.1,4,12,15,17,18,23,28,29,36–38 A cor-
relation between hypoperfusion in CTP and vasospastic
infarction was found. However, the retrospective design of
these studies, with inappropriate imaging time points and
perfusion measurements in preselected regions instead of
global brain perfusion, failed to show a therapeutically
relevant correlation between hypoperfusion and tissue at
risk for stroke development.11,15,17–19,23,25,33,36–38

Recently, whole-brain CTP became available, which
might at least overcome the problem of focal perfusion
measurement.10,25,37,38 The aim of this prospective study
was to evaluate the role of whole-brain CTP for the iden-
tification of tissue at risk for DCI and, thereby, of patients
at risk for developing DIND and/or vasospasm-associated
infarction, either 1) early after aSAH, prior to the vaso-
spasm period; 2) during rapidly progressive CTP-con-
firmed vasospasm with or without symptoms; and/or 3) on
Day 7 in patients who were comatose or sedated and could
not be neurologically assessed.

Use of the CTP Study

The CTP Algorithm

Investigation with CTP was routinely performed in all
patients in the acute phase (Days 3–5) after aSAH. In cas-
es of rapidly progressive TCD-vasospasm (BFV increase
> 50 cm/sec within 24 hours), CTP was repeated. Addi-
tionally, patients who were comatose and/or sedated were
routinely investigated with CTP on Day 7 after aSAH.
Thus, noncomatose and/or nonsedated patients without
TCD-vasospasm were imaged once, those with TCD-va-
sospasm at least twice; comatose and/or sedated patients
without TCD-vasospasm were imaged twice, and those
with TCD-vasospasm at least 3 times.

Imaging Protocol

All images were obtained on a 128-slice multidetector
CT scanner (Siemens Definition AS+; Siemens Healthcare
Sector). The following parameters were used for nonen-
hanced spiral neuro mode scan, covering skull base and
the cerebrum with a caudal-cranial range of 12 cm: 120
kV, 450 mAs, rotation time 1.0 second, maximum pitch
0.8, slice collimation 50 × 0.6 mm, kernel H31f, 512 ma-
trix. Routine axial and coronal maximum-projection re-
constructions were made, with a 5-mm slice thickness and
a 1-mm interslice distance.

The CTP data were acquired using a periodic spiral
approach (adaptive 4-dimensional spiral mode) of 30 pe-

Methods

A total of 43 patients with aSAH, who were admitted
between August 2012 and December 2013, were enrolled
in this prospective single-center study. The local institu-
tional review board approved the study protocol. Patients
who were younger than 18 years, pregnant, had severe
renal dysfunction, or admitted later than 24 hours after
bleeding were excluded. All patients were treated accord-
ing to the institute’s standard protocol for management
of patients with aSAH. All procedures followed were in
accordance with the ethical standards of the responsible
committee on human experimentation (institutional and
national) and with the Helsinki Declaration of 1975, as
revised in 2008.34

The diagnosis of aSAH was confirmed by a CT scan
and CT angiography (CTA) and/or DSA. The aneurysm
was either clipped or coiled within 48 hours after bleeding.
All patients were kept at the intensive care unit between
Day 0 and at least Day 14 post-aSAH. Blood flow veloc-
ity (BFV) was routinely measured using TCD on a daily
basis, starting with the day of admission. A mean BFV >
120 cm/sec was defined as TCD-confirmed vasospasm.11
DIND was defined as new neurological deterioration (e.g.,
aphasia, hemiparesis, confusion, consciousness alteration,
and so on) after exclusion of hydrocephalus, rebleeding,
seizures, and metabolic disturbances.9 Routine CT scans
were performed in every patient within 1 day after an-
erysm treatment to rule out treatment-induced ischemia
and on Day 10 after bleeding. In patients who underwent
aneurysm clipping, CTA was additionally obtained with
the first postoperative native CT scan (i.e., without appli-
cation of contrast media). DCI was defined as hypodensity
on CT scan, which was not visible on the posttreatment
CT scan and after excluding other causes. All patients re-
ceived intravenous nimodipine for 14 days. Normovolemia
was maintained in patients without TCD-vasospasm. In
any patient with TCD-vasospasm, noradrenaline was used
to induce arterial hypertension (target systolic blood pres-
sure 160–180 mm Hg). Some patients with symptomatic
vasospasm and CTP-proven perfusion deficits in the cor-
responding vessel territory, despite maximal conservative
antivasospastic treatment, underwent either intraarterial
application of nimodipine, balloon dilation, or a combina-
tion of both.
periodic spiral mode scans of the brain with cranial-caudal coverage of 96 mm in z-axis (1.5-second sampling time per volume). The CTP scan (80 kV, 200 mAs, rotation time 0.3 seconds, maximum pitch 0.5, collimation 2 × 64 × 0.6 mm) was started 4 seconds after the injection of a short contrast bolus (Imeron 400; Bracco Imaging) into a cubital vein. The contrast volume was 36 ml at a flow rate of 6 ml/sec, followed by a 30 ml saline chaser at 6 ml/sec.

For CTA (120 kV, 120 mAs, rotation time 0.3 seconds, pitch 0.6, collimation 2 × 64 × 0.6 mm), another 60 ml of contrast agent was injected with a biphasic protocol of 45 ml at 6 ml/sec and 15 ml at 3 ml/sec followed by a 30-ml saline chaser at 3 ml/sec. Routine reconstructions of CTP data were made with a slice width of 5 mm every 3 mm (kernel H20f, 512 matrix). CTP data were analyzed on a multimodality workstation (Siemens syngo 2010B) equipped with a commercially available software package (Volume Perfusion CT Neuro; Siemens), which calculates quantitative color-coded 3D maps of various cerebral perfusion parameters using a delay-invariant deconvolution method. The peak arterial scan was assigned by region of interest (ROI) analysis in the proximal A1 segment. In addition, CTA data were reconstructed with a slice thickness of 0.75 mm every 0.4 mm. Axial and coronal reconstructions of maximum-intensity projections (MIP), with a 10-mm slice thickness and a 3-mm interslice distance, were subsequently made.

Data Analysis

Two experienced neuroradiologists (P.S. and K.D.), who were blinded to all clinical data and the clinical course, assessed the CTP and CTA images. 3D perfusion parameter maps were used to show the distribution of hypoperfusion. Readers were asked to assess the presence of a focal hypoperfused area (defined as a visual abnormality) on any of the parameter maps consisting of cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), time to start (TTS), time to peak (TTP), and time to drain (TTD). If hypoperfusion was present, readers had to assign it to one of the vascular territories. Perfusion abnormalities that persisted on the basis of a primary hemorrhagic event, previous ischemia, or surgical intervention were excluded as acute perfusion deficits. Consensus judgment was determined after reviewing the images independently.

Axial and coronal CTA reconstructions were used to identify vasospasm or occlusion in the following vessels: proximal anterior cerebral artery (A1), middle cerebral artery (M1/M2), and the posterior cerebral artery (P). In cases with additional DSA, DSA was also used to spot vessel abnormalities. By definition, cerebral vasospasm is a focal narrowing of vessel diameter compared with the same segment in the initial CTA at the time of SAH. A vessel narrowing < 50% was considered as mild, 50%–75% as moderate, and > 75% as high-grade angiographic vasospasm.

In all patients, CTP parameter maps were used to make treatment decisions. Patients with symptoms of vasospasm, increased BFV in TCD, abnormal CTP data (defined as highly visual abnormality on the parameter maps in more than one-third of 1 or more vascular territories), and arterial vasospasm on single-phase CTA axial and coronal MIP reconstructions underwent DSA, with the possibility to perform endovascular treatment. The perfusion deficits were divided into 2 main groups of territorial and nonterritorial. Territorial perfusion deficits were diagnosed if the perfusion deficit was confined to a vessel territory (Fig. 1A). Nonterritorial perfusion deficits were diffuse deficits, including multiple vessel territories or the watershed area between 2 vessel territories (Fig. 1B).

Statistical Analysis

Fisher’s exact test was used to evaluate the sensitivity and specificity of perfusion deficits on CTP for the identification of patients at risk for developing DIND and tissue at risk for DCI, respectively. We used a paired t-test to assess the correlation between perfusion deficit on the CTP and DIND/DCI.

Results

A total of 43 patients were included in the study. The mean age of patients was 52.0 (29–82) years. Thirty patients were women and 13 were men. In all patients, aSAH was diagnosed within 24 hours after symptom onset, which was considered the moment of aneurysm rupture. Patients with history of minor leak and patients with ill-defined symptom onset were excluded. Multiple aneurysms were identified in 14 patients. By dichotomizing the Hunt and Hess grade to good (Grades I–III) and poor (Grades IV and V), we found a good Hunt and Hess grade in 23 of the 43 patients (53%). Thirty-nine of the 43 patients (91%) had a Fisher Grade 3 or 4 on the initial CT scan. The ruptured aneurysm was clipped in 25 patients and coiled in 18 patients. The posttreatment CT scan showed partial cerebellar infarction in 2 patients with coiled basilar artery aneurysm and infarction of the recurrent artery of Heubner in 1 patient with clipped anterior communicating artery aneurysm. The CT scan ruled out spatula-induced hypodensity/contusion in the frontal and temporal lobes in all clipped aneurysms. There was neither vasospasm in the postoperative CTA, which was performed with the native CT, nor in the final angiographic series after completion of coiling. A summary of patient characteristics is given in Table 1.

Incidence of DIND and DCI in the Study Population

Delayed ischemic neurological deficits occurred in 13 of the 43 patients (30%) within 2 weeks after aSAH, of whom 7 patients (54%) had a transient and 6 patients (46%) a permanent DIND. Vasospasm-associated DCI developed in 11 of the 43 patients (26%).

Early CTP (on Days 3–5) for Identification of Patients at Risk for DIND and of Tissue at Risk for DCI

In 39 of 43 patients (91%), early CTP was done on Day 3 after aSAH, in 1 patient (2%) on Day 4, and in 3 patients on Day 5 (7%); a delay of imaging beyond Day 3 occurred because of a nonfunctioning CT scanner. Perfusion deficits in CTP on Days 3–5 were seen in 14 of the 43 patients (33%), of whom 10 (72%) developed DIND (in 4 of these 10 patients, DIND occurred on Days 3–5 and in 6 patients...
on Days 5–14 after aSAH). Seven of the 10 patients (70%) with early perfusion deficits and DIND had territorial deficits and 3 patients (30%) had nonterritorial deficits.

The remaining 4 patients (28%) with early perfusion deficits (but without DIND) had nonterritorial perfusion deficits. Three patients (21%) developed DCI without preceding DIND, and 1 patient (7%) had neither DIND nor DCI. Three patients without early perfusion deficits in CTP later developed DIND; in these patients, a second CTP after Day 5 documented territorial perfusion deficits.

Delayed cerebral infarction occurred in 9 of the 14 patients (64%) with early perfusion deficits, of whom 6 patients (67%) had preceding DIND. In the remaining 3 patients (33%), DCI occurred without DIND. Two additional patients developed DCI, but did not demonstrate early perfusion deficits on CTP nor did they have preceding DIND.

The sensitivity and specificity of perfusion deficits on early CTP for the identification of patients at risk for developing DIND was 77% (95% CI 46%–95%) and 87% (95% CI 69%–96%), respectively, with a statistically significant correlation between early perfusion deficits on the CTP and the occurrence of DIND after aSAH (Pearson r = 0.62, 95% CI 40%–79%, p < 0.0001). The positive predictive value (PPV) was 71% (95% CI 42%–92%) and the negative predictive value (NPV) was 90% (95% CI 73%–98%) (Fig. 2A).

**Fig. 1.** Whole-brain CTP with perfusion deficits in the middle cerebral artery territory on the right side (A) and diffuse unspecific deficits (B). Figure is available in color online only.
Early CTP identified tissue at risk for developing vasospasm-associated DCI with a sensitivity of 82% (95% CI 48%–98%) and a specificity of 84% (95% CI 67%–95%). The PPV was 64% (95% CI 35%–87%) and the NPV was 93% (95% CI 77%–99%). Early perfusion deficits on CTP and the occurrence of vasospasm-associated DCI correlated significantly (Pearson r = 0.62, 95% CI 39%–77%, p = 0.0001) (Fig. 2B).

Use of CTP in Rapidly Progressive TCD-Vasospasm (daily increase in mean BFV > 50 cm/sec)

A rapid increase of TCD-measured mean BFV of > 50 cm/sec within 24 hours was detected in 8 of the 43 patients (19%). Despite the steep BFV increase, no perfusion deficit could be detected in 5 of the 8 patients (62.5%). None of these 5 patients developed DCI. However, 2 of the 5 patients without perfusion deficit later developed DIND. In the remaining 3 patients (37.5%), nonterritorial perfusion deficits were seen on CTP, of whom 2 patients (67%) developed DCI without preceding DIND and 1 patient (33%) had DIND without DCI. The sensitivity and specificity of CTP in rapidly progressive TCD-vasospasm for identification of patients at risk for DIND were 33% (95% CI 8%–90%) and 60% (95% CI 14%–94%), respectively, and the PPV and NPV were 33% (95% CI 9%–90%) and 60% (95% CI 14%–94%), respectively. The sensitivity and specificity of CTP in rapidly progressive TCD-vasospasm for identification of tissue at risk were 100% (95% CI 15%–100%) and 83% (95% CI 35%–99%), respectively, and the PPV and NPV were 67% (95% CI 9%–99%) and 100% (95% CI 47%–100%), respectively.

Use of CTP on Day 7 in Patients Who Were Comatose and/or Sedated

Seven of the 43 patients (16%) who were comatose and/or sedated on Day 7 after the initial bleeding received an additional CTP on Day 7. Four of these 7 patients (57%) had perfusion deficits on the CTP on Day 7, of whom 3 patients had nonterritorial and 1 patient had a territorial perfusion deficit. All 4 patients with perfusion deficits developed DCI. None of the 3 patients without perfusion deficits developed DCI.

Discussion

CT perfusion is a well-established tool in the imaging of ischemic stroke. Thus, it is not surprising that CTP was also used in the diagnostic workup after aSAH, with the aim to detect impending vasospastic infarction during the so-called vasospasm period between Days 5 and 14 after the initial bleeding. Early studies

Wintermark et al. performed a retrospective analysis of 27 patients with aSAH who were suspected to develop angiographic vasospasm and therefore underwent CTP/CTA, TCD, and DSA between Days 6 and 8 after the initial bleeding. They found a significant correlation of CTP/CTA findings with those of DSA. The most accurate CTP parameter (based on ROI analysis) in this study for the detection of angiographic vasospasm was MTT, with a cutoff at 6.4 seconds and a very high NPV of 98.7%. Sanelli et al. performed a retrospective analysis of a single ROI-based CTP in 75 patients between Day 0 and Day 3 after aSAH and found a statistically significant reduction of CBF and prolongation of MTT on early CTP in patients who develop angiographic vasospasm later. In a second retrospective study in 96 patients with aSAH, Sanelli et al. performed ROI-based CTP between Days 6 and 8 after aSAH and found a sensitivity of 78% and a specificity of 66% of CTP for the development of permanent neurological deficits and a sensitivity of 88% and a specificity of 59% for the development of DCI.

Earlier Studies

Wintermark et al. performed a retrospective analysis of 27 patients with aSAH who were suspected to develop angiographic vasospasm and therefore underwent CTP/CTA, TCD, and DSA between Days 6 and 8 after the initial bleeding. They found a significant correlation of CTP/CTA findings with those of DSA. The most accurate CTP parameter (based on ROI analysis) in this study for the detection of angiographic vasospasm was MTT, with a cutoff at 6.4 seconds and a very high NPV of 98.7%. Sanelli et al. performed a retrospective analysis of a single ROI-based CTP in 75 patients between Day 0 and Day 3 after aSAH and found a statistically significant reduction of CBF and prolongation of MTT on early CTP in patients who develop angiographic vasospasm later. In a second retrospective study in 96 patients with aSAH, Sanelli et al. performed ROI-based CTP between Days 6 and 8 after aSAH and found a sensitivity of 78% and a specificity of 66% of CTP for the development of permanent neurological deficits and a sensitivity of 88% and a specificity of 59% for the development of DCI.

In a retrospective ROI-based CTP study by Kunze et al., 53 patients with aSAH were examined on Day 3 or 4, Day 6 or 7, Days 9 and 10, and additionally at any other
time point when cerebral vasospasm was suspected. The CTP parameter with the highest sensitivity (93%) but a low specificity (27%) for the detection of angiographic vasospasm was TTP. With at least 3 CTP investigations per patient, the exposure to radiation was higher than in most other studies and in the present study. Killeen et al. performed ROI-based CTP in 97 consecutive aSAH patients between Days 6 and 8 and correlated in a retrospective analysis the CTP data with cerebral infarction and/or permanent neurological deficit. The sensitivity and specificity for the detection of infarction and/or permanent neurological deficit were 84% and 73%, respectively. Etminan and colleagues performed a retrospective study in 51 patients; they showed that an MTT increase within 12 hours after bleeding but before therapy is related to poor outcome.

In a prospective study, Hickmann et al. included 38 patients with aSAH. CTP and TCD measurements were performed on Days 3, 7, and 10 after aneurysm rupture. Hickmann and colleagues performed a semiquantitative and visual CTP analysis using 6 predefined ROIs. They concluded that TTP was the most sensitive and most specific predictor of clinically relevant vasospasm, defined as cerebral infarction and/or DIND (sensitivity of 90% and specificity of 61.1%). In a prospective study by Dankbaar et al., ROI-based CTP was performed at the time point of clinical deterioration in 42 patients with aSAH. The primary endpoint was the development of new focal neurological deficit or decreased Glasgow Coma Scale score of > 2 points, lasting > 2 hours. A vasospasm-induced new neurological deficit occurred in 25 patients. CTP had a sensitivity of 84% and a specificity of 79% for the diagnosis of new focal neurological deficit due to vasospasm at the time point of clinical deterioration.

All of these studies have significant limitations. One of them is validating parameter. In the studies by Wintemark et al., Sanelli et al., and Kunze et al., the role of CTP for cerebral vasospasm detection was defined by comparing CTP with DSA. However, only a minority of patients with angiographic vasospasm develop symptomatic vasospasm and possibly need initiation or intensification of the vasospastic therapy. Killeen et al. and, in part, Hickmann et al. compared CTP findings with DCI or permanent neurological deficit. However, the potential benefit of CTP is specific predictor of clinically relevant vasospasm, defined as cerebral infarction and/or DIND (sensitivity of 90% and specificity of 61.1%). In a prospective study by Dankbaar et al., ROI-based CTP was performed at the time point of clinical deterioration in 42 patients with aSAH. The primary endpoint was the development of new focal neurological deficit or decreased Glasgow Coma Scale score of > 2 points, lasting > 2 hours. A vasospasm-induced new neurological deficit occurred in 25 patients. CTP had a sensitivity of 84% and a specificity of 79% for the diagnosis of new focal neurological deficit due to vasospasm at the time point of clinical deterioration.

The rationale for study initiation was to attempt to overcome some of the aforementioned limitations of other studies. We used an imaging algorithm to 1) identify patients and tissue at risk before occurrence of fixed neurological deficits and DCI, 2) reduce the number of repeated scans to a minimum, and 3) obtain CTP data from defined and therefore comparable time points after aSAH. We planned to perform the first CTP on Day 3 for 2 reasons. First, TCD studies indicated Days 4–14 to be the vasospasm period. Second, studies by Sanelli et al. and Etminan et al. have shown that patients who later develop angiographic vasospasm already had a CBF reduction and an MTT prolongation on a Day 0 to Day 3 CTP. In surgical cases, spatula pressure could induce prolonged frontal and temporal hypoperfusion; therefore, we refrained from CTP on Days 0–2. We were able to perform CTP on Day 3 in the vast majority of included patients, but CTP had to be postponed in 1 patient to Day 4 and in 3 patients to Day 5 due to a nonfunctioning CT scanner, which might represent some of the aforementioned limitations of other studies. We used an imaging algorithm to 1) identify patients and tissue at risk before occurrence of fixed neurological deficits and DCI, 2) reduce the number of repeated scans to a minimum, and 3) obtain CTP data from defined and therefore comparable time points after aSAH. We planned to perform the first CTP on Day 3 for 2 reasons. First, TCD studies indicated Days 4–14 to be the vasospasm period. Second, studies by Sanelli et al. and Etminan et al. have shown that patients who later develop angiographic vasospasm already had a CBF reduction and an MTT prolongation on a Day 0 to Day 3 CTP. In surgical cases, spatula pressure could induce prolonged frontal and temporal hypoperfusion; therefore, we refrained from CTP on Days 0–2. We were able to perform CTP on Day 3 in the vast majority of included patients, but CTP had to be postponed in 1 patient to Day 4 and in 3 patients to Day 5 due to a nonfunctioning CT scanner, which might represent some of the aforementioned limitations of other studies. We used an imaging algorithm to 1) identify patients and tissue at risk before occurrence of fixed neurological deficits and DCI, 2) reduce the number of repeated scans to a minimum, and 3) obtain CTP data from defined and therefore comparable time points after aSAH. We planned to perform the first CTP on Day 3 for 2 reasons. First, TCD studies indicated Days 4–14 to be the vasospasm period. Second, studies by Sanelli et al. and Etminan et al. have shown that patients who later develop angiographic vasospasm already had a CBF reduction and an MTT prolongation on a Day 0 to Day 3 CTP.
Can CTP on Day 3 Predict DIND and DCI?

In the present study, 31% of all patients developed DIND, which is in line with the percentage previously described in the literature.27,33 The most important result of the study was that whole-brain CTP routinely performed on Day 3 has a high sensitivity and specificity for the identification of patients at risk for the development of DIND, allowing early initiation or intensification of antivasospastic therapy. The sensitivity was 77%, which is comparable with the reported sensitivity of CTP in the vasospasm phase and only slightly lower compared with the sensitivity of CTP performed at the time of clinical deterioration, which could be too late to avoid permanent neurological deficits or infarction. The specificity of early whole-brain CTP was 87%, which was even higher than in other studies. Our results clearly indicate that whole-brain CTP scanning on Day 3 after aSAH has sufficient diagnostic accuracy with the lowest possible radiation exposure; it provides an early diagnosis, allowing for initiation of appropriate treatment.

Can TCD, as a Pretest, Reduce the Number of Additional CTP Investigations?

Transcranial Doppler sonography is an established monitoring tool for the identification of cerebral vasospasm after aSAH. With the aim to reduce the number of repeated CTP scans, we tried to use TCD for identification of patients at risk. Repeat CTP was only performed in patients with a BFV increase > 50 cm/sec within 24 hours. This was based on the study by Rätsep et al., who found a correlation of cerebral hemodynamic impairment with severe vasospasm and with a rapid increase in TCD-BFV.30 We showed that an increase in TCD-BFV usually lags 1 or 2 days behind the identification of perfusion deficits shown by CTP. Accordingly, we found no statistically significant correlation between TCD-BFV increase and perfusion deficits on CTP. Thus, we can conclude that the parameter of TCD-BFV increase alone is not suitable for the detection of tissue at risk.

Concerning the detection of tissue at risk, whole-brain CTP should be an essential part of the diagnostic work-up in addition to daily clinical assessment and daily BFV measurement by TCD. These findings are supported by the study by Pham et al., which evaluated the diagnostic accuracy of CTP and TCD for the prediction of DCI between Days 3 and 14 after aSAH. They performed qualitative visual analysis of the CTP maps and quantitative analysis based on predefined ROIs and found a good prediction of DCI by CTP at a median of 3 days before infarction manifestation. In line with our findings, TCD measurements failed to predict the occurrence of DCI.24 In contrast, in a retrospective study of 45 patients with aSAH, Toi et al. reported that TCD in the early stage of aSAH can predict the future occurrence of symptomatic vasospasm. In their study, the highest sensitivity (71.4%) and specificity (68.1%) were seen on Day 3, with a BFV threshold of 72.5 cm/sec.31

Whole-Brain CTP on Day 7 After aSAH in Patients Who Were Comatose and/or Sedated

The identification of impending DIND or DCI in patients with high-grade aSAH is difficult due to a decreased possibility of neurological assessment. Therefore, we repeated CTP on Day 7 after aSAH in patients who were comatose and/or sedated. Perfusion deficits were seen in 4 of the 7 patients who were comatose and/or sedated. Interestingly, the initial CTP had already demonstrated perfusion deficits in these patients, of whom all developed DCI. This suggests that the information gain by repeated CTP on Day 7 in patients who are comatose and/or sedated is low and too late for initiation of appropriate antivasospastic therapy. However, the number of patients is far too low to draw any final conclusion concerning the diagnostic value of CTP on Day 7 after aSAH in patients who are comatose and/or sedated.

Does CTP Improve Outcome?

The overall aim of using TCD and DSA for vasospasm identification, and of using CTP for identification of tissue at risk for DCI, was to improve outcome. We showed that early CTP has a high PPV and NPV for DIND and DCI. However, the study design did not allow us to determine if that high PPV translates into better outcome. All patients with proven territorial hypoperfusion in CTP and artery narrowing in CTA underwent further endovascular therapy and/or induced hypertension. However, the treatment was not standardized for purposes of the study, and treatment failure, which is frequent in patients with severe vasospasm despite timely recognition of tissue at risk by CTP, was not defined. We strongly believe that a larger study, which perhaps could not be conducted at a single center, would be necessary to address the issue of outcome improvement by CTP.

The study also did not allow us to answer the question of whether CTP is superior to routine angiography during the vasospasm period or to measurement of ptiO2 (brain tissue oxygen partial pressure), because no comparison between the tools was performed. However, the study allowed us to gain information on the value of CTP compared with clinical examination and TCD. We showed that 1) CTP on Day 3 (i.e., before the majority of patients become clinically symptomatic) has a high sensitivity and specificity for the identification of patients at risk for the development of DIND, and 2) the increase in TCD-BFV usually lags 1 or 2 days behind the identification of perfusion deficits by CTP. These findings suggest that early CTP might be a better tool than clinical examination and TCD for timely identification of patients at risk.

Strengths and Limitations of the Study

Strengths of this study include its prospective nature, the use of a rigid CTP algorithm, the focus on an increase in sensitivity as well as an avoidance of unnecessary radiation exposure, and the use of whole-brain CTP in patients with aSAH for the first time. We had to delay early CTP in 9% of patients to Days 4 and 5 due to logistic reasons, which might represent a limitation. However, none of the patients had clinical signs of vasospasm or BFV > 120 cm/sec. The number of included patients is still too small to consistently answer distinct questions in subgroup analyses. Furthermore, the results of the present study, as well as those of previous studies concerning sensitivity and speci-
ficity, are hampered by the fact that the CTP findings led to initiation of therapies with varying efficacy to reverse the detected perfusion deficits.

Conclusions

Whole-brain CTP is a rapid imaging technique that allows early identification of patients at risk for developing DIND and tissue at risk for vasospasm-induced infarction within days after aSAH. On the basis of this study’s findings, a routine use of whole-brain CTP in the acute phase of aSAH seems to be useful.

References


Disclosures
Prof. Moerer gave lectures on mechanical ventilation and hemodynamic monitoring at regional workshops and industry-sponsored sessions within the context of a national congress and received speaker’s honoraria from Pulsion Medical, Hill-Rom, and MAQUET Critical Care.

Author Contributions
Conception and design: Malinova, Moerer, Rohde, Mielke. Acquisition of data: Malinova, Dolatowski, Schramm. Analysis and interpretation of data: Malinova, Dolatowski, Schramm, Rohde, Mielke. Writting the article: Malinova. Critically revising the article: Schramm, Moerer, Rohde, Mielke. Reviewed submitted version of manuscript: Moerer, Rohde. Approved the final version of the manuscript on behalf of all authors: Malinova. Statistical analysis: Malinova. Administrative/technical/material support: Dolatowski, Schramm. Study supervision: Moerer, Rohde, Mielke.

Correspondence
Vesna Malinova, Department of Neurosurgery, Georg-August-University, Robert-Koch-Straße 40, Göttingen 37075, Germany. Email: vesna.malinova@gmail.com.